Multiplex Mass Spectrometry Analysis of Amyloid Proteins in Human Plasma for Alzheimer's Disease Diagnosis

Direct analysis of amyloid proteins in human plasma will promote rapid screening of brain amyloidosis, the earliest pathological signature of Alzheimer's disease. We developed a microflow liquid chromatography-targeted mass spectrometry assay for quantitation of four intact beta-amyloid proteins starting from 1 mL of human plasma samples. This method showed 90% accuracy for predicting brain amyloid using plasma A beta 42/A beta 40 values from 36 cognitively normal individuals in a prospective clinical study (raw data deposited in MassIVE, Data set ID MSV000087451). Our method may contribute to early diagnosis of Alzheimer's disease.

Automated summary

Direct analysis of amyloid proteins in human plasma can facilitate rapid screening for the earliest pathological signature of Alzheimer's disease. A developed microflow liquid chromatography-targeted mass spectrometry assay showed 90% accuracy in predicting brain amyloid using plasma A beta 42/A beta 40 values from 36 cognitively normal individuals, potentially contributing to early diagnosis of Alzheimer's disease.